Aloxi palonosetron regulatory update

EC approved an MAA for Aloxi palonosetron to prevent nausea and vomiting associated with emetogenic cancer chemotherapy. The serotonin (5-HT3) receptor antagonist was approved in the U.S. in 2003. ...